Patents by Inventor Michael Tobias Stumpp
Michael Tobias Stumpp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210069293Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: ApplicationFiled: April 9, 2020Publication date: March 11, 2021Inventors: Hans Kaspar BINZ, Patrik FORRER, Michael Tobias STUMPP
-
Patent number: 10646542Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: November 14, 2017Date of Patent: May 12, 2020Assignee: Molecular Partners AGInventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Publication number: 20180125932Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: ApplicationFiled: November 14, 2017Publication date: May 10, 2018Inventors: HANS KASPAR BINZ, PATRIK FORRER, MICHAEL TOBIAS STUMPP
-
Patent number: 9849158Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: February 4, 2016Date of Patent: December 26, 2017Assignee: Molecular Partners AGInventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Patent number: 9657287Abstract: A repeat protein from a collection of repeat proteins, wherein each repeat protein of said collection comprises a repeat domain, which comprises a set of consecutive repeat modules, wherein the repeat modules have the same fold and stack tightly to create a superhelical structure having a joint hydrophobic core, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins of the collection differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described as are related pharmaceuticals and nucleic acid molecules.Type: GrantFiled: March 3, 2015Date of Patent: May 23, 2017Assignee: Universitat ZurichInventors: Michael Tobias Stumpp, Patrik Forrer, Hans Kaspar Binz, Andreas Pluckthun
-
Publication number: 20160263185Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: ApplicationFiled: February 4, 2016Publication date: September 15, 2016Inventors: Hans Kaspar BINZ, Patrik FORRER, Michael Tobias STUMPP
-
Patent number: 9365629Abstract: The invention relates to collections of target-specific designed binding proteins based on armadillo repeat proteins, and to a method of generating them. Designed armadillo repeat proteins are based on consensus sequences of single armadillo repeat units. These repeat proteins can be used as scaffolds for peptide recognition. Such a scaffold provides a binding mode that is in principle the same for every small recognizable unit, e.g. an amino acid or dipeptide, allowing a precise and modular recognition of a peptide in extended conformation. The method allows to generate a series of modules recognizing these simple units, and to combine such building blocks to create a binding site for any desired peptide target without performing additional selections.Type: GrantFiled: September 23, 2008Date of Patent: June 14, 2016Assignee: University of ZurichInventors: Fabio Parmeggiani, Riccardo Pellarin, Anders Peter Larsen, Gautham Varadamsetty, Michael Tobias Stumpp, Andreas Plückthun
-
Patent number: 9289466Abstract: The present invention relates to binding proteins specific for Vascular Endothelial Growth Factor A (VEGF-A), in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx (wherein xxx denotes the amino acid length of the VEGF-A mature protein) binding to Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2). Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: March 12, 2014Date of Patent: March 22, 2016Assignee: Molecular Partners AGInventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Publication number: 20150344539Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: ApplicationFiled: October 28, 2014Publication date: December 3, 2015Inventors: Hans Kaspar BINZ, Patrik Forrer, Michael Tobias Stumpp
-
Publication number: 20150275201Abstract: A repeat protein from a collection of repeat proteins, wherein each repeat protein of said collection comprises a repeat domain, which comprises a set of consecutive repeat modules, wherein the repeat modules have the same fold and stack tightly to create a superhelical structure having a joint hydrophobic core, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins of the collection differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described as are related pharmaceuticals and nucleic acid molecules.Type: ApplicationFiled: March 3, 2015Publication date: October 1, 2015Inventors: Michael Tobias Stumpp, Patrik Forrer, Hans Kaspar Binz, Andreas Pluckthun
-
Patent number: 9006389Abstract: A repeat protein from a collection of repeat proteins, wherein each repeat protein of said collection comprises a repeat domain, which comprises a set of consecutive repeat modules, wherein the repeat modules have the same fold and stack tightly to create a superhelical structure having a joint hydrophobic core, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins of the collection differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described as are related pharmaceuticals and nucleic acid molecules.Type: GrantFiled: December 19, 2011Date of Patent: April 14, 2015Assignee: Universitat ZurichInventors: Michael Tobias Stumpp, Patrik Forrer, Hans Kaspar Binz, Andreas Pluckthun
-
Patent number: 8901076Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: November 3, 2009Date of Patent: December 2, 2014Assignee: Molecular Partner AGInventors: Hans Kasper Binz, Patrik Forrer, Michael Tobias Stumpp
-
Publication number: 20140221295Abstract: The present invention relates to binding proteins specific for Vascular Endothelial Growth Factor A (VEGF-A), in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx (wherein xxx denotes the amino acid length of the VEGF-A mature protein) binding to Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2). Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: ApplicationFiled: March 12, 2014Publication date: August 7, 2014Applicant: Molecular Partners AGInventors: Hans Kaspar BINZ, Patrik FORRER, Michael Tobias STUMPP
-
Patent number: 8710187Abstract: The present invention relates to binding proteins specific for Vascular Endothelial Growth Factor A (VEGF-A), in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx (wherein xxx denotes the amino acid length of the VEGF-A mature protein) binding to Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2). Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: April 29, 2011Date of Patent: April 29, 2014Assignee: Molecular Partners AGInventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Publication number: 20130116197Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: ApplicationFiled: April 29, 2011Publication date: May 9, 2013Inventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Publication number: 20120142611Abstract: A repeat protein from a collection of repeat proteins, wherein each repeat protein of said collection comprises a repeat domain, which comprises a set of consecutive repeat modules, wherein the repeat modules have the same fold and stack tightly to create a superhelical structure having a joint hydrophobic core, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins of the collection differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described as are related pharmaceuticals and nucleic acid molecules.Type: ApplicationFiled: December 19, 2011Publication date: June 7, 2012Applicant: UNIVERSITAT ZURICHInventors: Michael Tobias STUMPP, Patrik Forrer, Hans Kaspar Binz, Andreas Pluckthun
-
Patent number: 8110653Abstract: A collection of repeat proteins, each repeat protein comprising a repeat domain, which comprises a set of consecutive repeat modules, wherein each of the repeat modules is derived from one or more repeat units and wherein the repeat units comprise framework residues, which contribute to the folding topology of the repeat unit or contribute to an interaction with a neighboring repeat unit, and target interaction residues, which contribute to an interaction with a target substance, wherein the repeat proteins differ from other repeat proteins in the collection in at least one amino acid position of the repeat modules is described.Type: GrantFiled: August 11, 2008Date of Patent: February 7, 2012Assignee: Universitat ZurichInventors: Michael Tobias Stumpp, Patrik Forrer, Hans Kasper Binz, Andreas Pluckthun
-
Publication number: 20110224100Abstract: The invention relates to collections of target-specific designed binding proteins based on armadillo repeat proteins, and to a method of generating them. Designed armadillo repeat proteins are based on consensus sequences of single armadillo repeat units. These repeat proteins can be used as scaffolds for peptide recognition. Such a scaffold provides a binding mode that is in principle the same for every small recognizable unit, e.g. an amino acid or dipeptide, allowing a precise and modular recognition of a peptide in extended conformation. The method allows to generate a series of modules recognizing these simple units, and to combine such building blocks to create a binding site for any desired peptide target without performing additional selections.Type: ApplicationFiled: September 21, 2008Publication date: September 15, 2011Inventors: Fabio Parmeggiani, Riccardo Pellarin, Anders Peter Larsen, Gautham Varadamsetty, Michael Tobias Stumpp, Andreas Plückthun
-
Publication number: 20110207668Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: ApplicationFiled: November 3, 2009Publication date: August 25, 2011Inventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Publication number: 20090082274Abstract: The present invention relates to collections of repeat proteins comprising repeat modules which are derived from one or more repeat units of a family of naturally occurring repeat proteins, to collections of nucleic acid molecules encoding said repeat proteins, to methods for the construction and application of such collections and to individual members of such collections.Type: ApplicationFiled: August 11, 2008Publication date: March 26, 2009Applicant: Universitat ZurichInventors: Michael Tobias Stumpp, Patrik Forrer, Hans Kasper Binz, Andreas Pluckthun